Neoadjuvant nab-paclitaxel and gemcitabine in borderline resectable or locally advanced unresectable pancreatic adenocarcinoma in patients who are ineligible for FOLFIRINOX

Shawn L. Peterson; Muhammad Husnain; Terri Pollack; Agustin Pimentel; Arturo Loaiza-Bonilla; Colleen Westendorf-Overley; Kelley Ratermann; Lowell Anthony; Philip Desimone; Gaurav Goel; Mahesh Kudrimoti; Sean Dineen; Ching Wei D. Tzeng; Peter J. Hosein

doi:10.21873/anticanres.12692

Neoadjuvant nab-paclitaxel and gemcitabine in borderline resectable or locally advanced unresectable pancreatic adenocarcinoma in patients who are ineligible for FOLFIRINOX

Shawn L. Peterson, Muhammad Husnain, Terri Pollack, Agustin Pimentel, Arturo Loaiza-Bonilla, Colleen Westendorf-Overley, Kelley Ratermann, Lowell Anthony, Philip Desimone, Gaurav Goel, Mahesh Kudrimoti, Sean Dineen, Ching Wei D. Tzeng, Peter J. Hosein

Surgical Oncology

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Background/Aim: Combination nab-paclitaxel/ gemcitabine (AG) is superior to gemcitabine in patients with metastatic pancreatic cancer (PC). There are limited data for AG in borderline resectable (BR) or locally advanced pancreatic cancer (LAPC). Herein, we report our experience with neoadjuvant AG for BR/LAPC in patients ineligible for FOLFIRINOX. Patients and Methods: This retrospective series, included patients with BR/LAPC who received AG as neoadjuvant therapy for 3-4 months followed by radiation, then re-evaluation for surgery. Results: Between 10/2013-2/2018, 32 patients (22 BR, 10 LAPC) were treated with this approach. Median age was 70 years. Nine patients were converted to resectability by imaging; six had R0 resections (19%), five (16%) achieved a partial response and 24 (75%) had stable disease. Conclusion: In this small series, the R0 resection rate and response rate were 19% and 16% respectively. These data suggest that neoadjuvant AG may be an alternate option for patients ineligible for FOLFIRINOX.

Original language	English (US)
Pages (from-to)	4035-4039
Number of pages	5
Journal	Anticancer research
Volume	38
Issue number	7
DOIs	https://doi.org/10.21873/anticanres.12692
State	Published - Jul 2018

Keywords

Gemcitabine
Locally advanced
Nab-paclitaxel
Neoadjuvant
Pancreatic cancer

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.21873/anticanres.12692

Cite this

Peterson, S. L., Husnain, M., Pollack, T., Pimentel, A., Loaiza-Bonilla, A., Westendorf-Overley, C., Ratermann, K., Anthony, L., Desimone, P., Goel, G., Kudrimoti, M., Dineen, S., Tzeng, C. W. D., & Hosein, P. J. (2018). Neoadjuvant nab-paclitaxel and gemcitabine in borderline resectable or locally advanced unresectable pancreatic adenocarcinoma in patients who are ineligible for FOLFIRINOX. Anticancer research, 38(7), 4035-4039. https://doi.org/10.21873/anticanres.12692

Peterson, SL, Husnain, M, Pollack, T, Pimentel, A, Loaiza-Bonilla, A, Westendorf-Overley, C, Ratermann, K, Anthony, L, Desimone, P, Goel, G, Kudrimoti, M, Dineen, S, Tzeng, CWD & Hosein, PJ 2018, 'Neoadjuvant nab-paclitaxel and gemcitabine in borderline resectable or locally advanced unresectable pancreatic adenocarcinoma in patients who are ineligible for FOLFIRINOX', Anticancer research, vol. 38, no. 7, pp. 4035-4039. https://doi.org/10.21873/anticanres.12692

@article{64618a7957c240bfbe7c8b700bb49407,

title = "Neoadjuvant nab-paclitaxel and gemcitabine in borderline resectable or locally advanced unresectable pancreatic adenocarcinoma in patients who are ineligible for FOLFIRINOX",

abstract = "Background/Aim: Combination nab-paclitaxel/ gemcitabine (AG) is superior to gemcitabine in patients with metastatic pancreatic cancer (PC). There are limited data for AG in borderline resectable (BR) or locally advanced pancreatic cancer (LAPC). Herein, we report our experience with neoadjuvant AG for BR/LAPC in patients ineligible for FOLFIRINOX. Patients and Methods: This retrospective series, included patients with BR/LAPC who received AG as neoadjuvant therapy for 3-4 months followed by radiation, then re-evaluation for surgery. Results: Between 10/2013-2/2018, 32 patients (22 BR, 10 LAPC) were treated with this approach. Median age was 70 years. Nine patients were converted to resectability by imaging; six had R0 resections (19%), five (16%) achieved a partial response and 24 (75%) had stable disease. Conclusion: In this small series, the R0 resection rate and response rate were 19% and 16% respectively. These data suggest that neoadjuvant AG may be an alternate option for patients ineligible for FOLFIRINOX.",

keywords = "Gemcitabine, Locally advanced, Nab-paclitaxel, Neoadjuvant, Pancreatic cancer",

author = "Peterson, {Shawn L.} and Muhammad Husnain and Terri Pollack and Agustin Pimentel and Arturo Loaiza-Bonilla and Colleen Westendorf-Overley and Kelley Ratermann and Lowell Anthony and Philip Desimone and Gaurav Goel and Mahesh Kudrimoti and Sean Dineen and Tzeng, {Ching Wei D.} and Hosein, {Peter J.}",

year = "2018",

month = jul,

doi = "10.21873/anticanres.12692",

language = "English (US)",

volume = "38",

pages = "4035--4039",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "7",

}

TY - JOUR

T1 - Neoadjuvant nab-paclitaxel and gemcitabine in borderline resectable or locally advanced unresectable pancreatic adenocarcinoma in patients who are ineligible for FOLFIRINOX

AU - Peterson, Shawn L.

AU - Husnain, Muhammad

AU - Pollack, Terri

AU - Pimentel, Agustin

AU - Loaiza-Bonilla, Arturo

AU - Westendorf-Overley, Colleen

AU - Ratermann, Kelley

AU - Anthony, Lowell

AU - Desimone, Philip

AU - Goel, Gaurav

AU - Kudrimoti, Mahesh

AU - Dineen, Sean

AU - Tzeng, Ching Wei D.

AU - Hosein, Peter J.

PY - 2018/7

Y1 - 2018/7

N2 - Background/Aim: Combination nab-paclitaxel/ gemcitabine (AG) is superior to gemcitabine in patients with metastatic pancreatic cancer (PC). There are limited data for AG in borderline resectable (BR) or locally advanced pancreatic cancer (LAPC). Herein, we report our experience with neoadjuvant AG for BR/LAPC in patients ineligible for FOLFIRINOX. Patients and Methods: This retrospective series, included patients with BR/LAPC who received AG as neoadjuvant therapy for 3-4 months followed by radiation, then re-evaluation for surgery. Results: Between 10/2013-2/2018, 32 patients (22 BR, 10 LAPC) were treated with this approach. Median age was 70 years. Nine patients were converted to resectability by imaging; six had R0 resections (19%), five (16%) achieved a partial response and 24 (75%) had stable disease. Conclusion: In this small series, the R0 resection rate and response rate were 19% and 16% respectively. These data suggest that neoadjuvant AG may be an alternate option for patients ineligible for FOLFIRINOX.

AB - Background/Aim: Combination nab-paclitaxel/ gemcitabine (AG) is superior to gemcitabine in patients with metastatic pancreatic cancer (PC). There are limited data for AG in borderline resectable (BR) or locally advanced pancreatic cancer (LAPC). Herein, we report our experience with neoadjuvant AG for BR/LAPC in patients ineligible for FOLFIRINOX. Patients and Methods: This retrospective series, included patients with BR/LAPC who received AG as neoadjuvant therapy for 3-4 months followed by radiation, then re-evaluation for surgery. Results: Between 10/2013-2/2018, 32 patients (22 BR, 10 LAPC) were treated with this approach. Median age was 70 years. Nine patients were converted to resectability by imaging; six had R0 resections (19%), five (16%) achieved a partial response and 24 (75%) had stable disease. Conclusion: In this small series, the R0 resection rate and response rate were 19% and 16% respectively. These data suggest that neoadjuvant AG may be an alternate option for patients ineligible for FOLFIRINOX.

KW - Gemcitabine

KW - Locally advanced

KW - Nab-paclitaxel

KW - Neoadjuvant

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=85049792753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049792753&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12692

DO - 10.21873/anticanres.12692

M3 - Article

C2 - 29970528

AN - SCOPUS:85049792753

SN - 0250-7005

VL - 38

SP - 4035

EP - 4039

JO - Anticancer research

JF - Anticancer research

IS - 7

ER -

Neoadjuvant nab-paclitaxel and gemcitabine in borderline resectable or locally advanced unresectable pancreatic adenocarcinoma in patients who are ineligible for FOLFIRINOX

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this